Erythropoeitin production by electrical stimulation

Patent metadata

Field	Value
Publication number	US-10201705-B2
Application number	US-201715436397-A
Country	US
Kind code	B2
Filing date	Feb 17, 2017
Priority date	Mar 15, 2013
Publication date	Feb 12, 2019
Grant date	Feb 12, 2019

Abstract

Described herein are methods, devices, and systems for treating human anemia. The methods, devices, and systems generally include monitoring a patient's hemoglobin level and at least one of autonomic balance and inflammatory state to determine the etiology of the anemic state, modulating at least one of a sympathetic or parasympathetic nerve based on the cause of the anemia, monitoring for changes in the patient's cardiac activity and state of inflammation, and hemoglobin level. An external neurostimulation system is describes, and well as a chronic implantable system. A method for treating a patient for anemia in conjunction with a renal denervation ablation catheter is also disclosed.

First claim

What is claimed is:

1. A method of triggering neurostimulation to treat anemia in a heart failure patient, the method comprising:
using a microprocessor within a neuromodulation device to determine triggering conditions, wherein the triggering conditions comprise:
the patient's heart rate is within a specific heart range;
the patient's heart condition is stable; and
cardiac ischemia is not ongoing; and

initiating neurostimulation using the neuromodulation device to treat anemia when the triggering conditions are determined to be met.

2. The method of claim 1 , wherein neurostimulation comprises stimulation of a sympathetic nerve affecting erythropoietin (EPO) production.

3. The method of claim 1 , wherein neurostimulation comprises stimulation of a parasympathetic nerve affecting inflammation.

4. The method of claim 3 , wherein the parasympathetic nerve is a vagus nerve.

5. The method of claim 4 , wherein the vagus nerve innervates the celiac-superior mesenteric plexus ganglion.

6. The method of claim 4 , wherein the vagus nerve is a cervical vagus nerve.

7. The method of claim 1 , wherein the triggering conditions further comprise: bleeding is not ongoing.

8. The method of claim 1 , wherein the triggering conditions further comprise: a preprogrammed time of day.

9. The method of claim 1 further comprising:
obtaining cardiogenic impedance measurements from a plurality of vectors;
using the cardiogenic impedance measurements to determine cardiac integrity; and
using the cardiac integrity for feedback in determining stimulation parameters for nuerostimulation of a sympathetic nerve affecting erythropoietin (EPO) production.

10. The method of claim 1 further comprising ablating renal nerves of the patient using an ablation catheter.

Assignees

• Pacesetter Inc

Inventors

• Bharmi Rupinder
• Rosenberg Stuart
• Rooke Ryan
• Karst Edward
• Farazi Taraneh Ghaffari

Classifications

• A61B5/14503 Primary

  invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors (A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence) · CPC title

• A61B18/1492

  having a flexible, catheter-like structure, e.g. for heart ablation (A61B18/1477 takes precedence) · CPC title

• A61B2018/00511

  Kidney · CPC title

• A61N1/36034 Primary

  specified by the stimulation parameters · CPC title

• A61B2018/00577

  Ablation · CPC title